Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0International Journal of Molecular Sciences

Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells

5 affiliations
  1. 1Department of Molecular Biology and Human Genetics, Tzu-Chi University, Hualien 970, Taiwan
  2. 2Department of Medical Laboratory Science and Biotechnology, Taipei Medical University, Taipei 110, Taiwan
  3. 3Department of Pediatrics, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 231, Taiwan
  4. 4Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan
  5. 5Department of Chemistry, Tamkang University, Tamsui Dist., New Taipei City 251, Taiwan

Abstract

Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.

Related

  1. Phytochemical analyses, antimicrobial, antioxidant and anticancer activities of endophytic fungi from leaves of Reseda pruinosa
    Amr H Hashem, Nosiba S Basher, Abeer S Aloufi +12
    PLOS OnePeer-reviewedCC BYFull textGeneral biochemistryGenetics & genomicsPLOSEurope PMCPMC
  2. Investigating the anticancer potential of phytochemicals from the mangrove Rhizophora mucronata as inhibitors of lung cancer-associated proteins: Insights from multiscale computational and in silico analyses
    Zena Abdul-Ameer Mahdi, Batool Shakir Abed AlmjalawI, Mollah Naimuzzaman +8
    PLOS OnePeer-reviewedCC BY 4.0Full textProteomics & metabolomicsPlant biologyPLOS
  3. Evaluation of Unique Multidentate Fluoroquinolones as Potential Anticancer and Antimicrobial Compounds Reinforced by Docking Mechanistic Studies on Topoisomerase II and Glyoxalase I with Dual Antioxidative–Anti-Inflammatory Effects
    Noor Mamdooh, Yusuf Al-Hiari, Violet Kasabri +6
    BiomoleculesPeer-reviewedCC BY 4.0General biochemistryCrossref
  4. Integrated In vitro and in vivo evaluation of anticancer potentials of two clerodane diterpenes isolated from Psidium guajava (L.) through molecular docking approaches
    Most Chand Sultana Khatun, Mir Imam Ibne Wahed, Md. Jamal Hossain +3
    PLOS OnePeer-reviewedCC BY 4.0Proteomics & metabolomicsCell biologyPLOS
  5. Evaluation of the Anticancer Potential of Compound 107 via the VEGFA and VEGFR2 (KDR) Signaling Pathway in Colorectal Cancer: Integrative Analysis of Clinical, In Silico, and In Vitro Approaches
    Ayca Tas, Cemile Zontul, Gökhan Dogan +11
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Molecular biology & gene regulationCrossref
BibTeX
@article{lin2026anticancer,
  title = {{Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells}},
  author = {Guan-Ling Lin and Jen-Che Chang and Yue-Cen Lai and Te-Sheng Lien and Der-Shan Sun and Ching-Feng Cheng and Lian-Fu Yang and Ruo-Chia Tseng and Yu-Jui Su and Hsin-Ying Wu and Tzenge-Lien Shih and Hsin-Hou Chang},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  month = nov,
  doi = {10.3390/ijms272210279},
  url = {https://www.mdpi.com/1422-0067/27/22/10279},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Anticancer Evaluation and Cellular-Stress Analyses of a Flavonol–Ruthenium(II) Complex Against Aggressive Breast Cancer Cells
AU  - Guan-Ling Lin
AU  - Jen-Che Chang
AU  - Yue-Cen Lai
AU  - Te-Sheng Lien
AU  - Der-Shan Sun
AU  - Ching-Feng Cheng
AU  - Lian-Fu Yang
AU  - Ruo-Chia Tseng
AU  - Yu-Jui Su
AU  - Hsin-Ying Wu
AU  - Tzenge-Lien Shih
AU  - Hsin-Hou Chang
PY  - 2026
DA  - 2026/11/16
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms272210279
UR  - https://www.mdpi.com/1422-0067/27/22/10279
AB  - Triple-negative breast cancer remains refractory to conventional chemotherapy, driving demand for selective metallopharmaceuticals that trigger immunogenic cell death and convert immune-desert “cold” tumors into immune-vulnerable “hot” tumors. Here, we delineate the in vitro efficacy and regulated cell death (RCD) landscape of compound 2 [RuCl(p-cymene)(4′-methoxyflavonol)], a half-sandwich Ru(II)–arene flavonol complex assembled from 3-hydroxy-4′-methoxyflavone and dichloro(p-cymene)ruthenium(II) dimer. Under 24 h CCK-8 assays, compound 2 potently inhibited aggressive breast cancer models—human MDA-MB-231 IC50 37.6 μM and murine 4T1 IC50 26.1 μM—while sparing non-malignant human mammary epithelial H184B5F5/M10 (IC50 72.6 μM, SI 1.9) and mouse embryonic fibroblasts (IC50 41.3 μM, SI 1.6), showing activity comparable to cisplatin (IC50 41.2 μM in MDA-MB-231) and superior to free ligand + Ru-dimer mixture (IC50 108.9 μM). Compound 2 exhibited favorable physiological stability and enhanced stability under mildly acidic, tumor-mimetic conditions, supporting a tumor-retentive prodrug behavior. CTS-RCDP multiparametric flow cytometry revealed a multimodal death network predominantly driven by pyroptosis (51.7% in MDA-MB-231, 40.1% in 4T1), accompanied by apoptosis, validated by caspase-1/-3 colorimetric assays (3.2-fold/2.4-fold increase, p < 0.01). This was coupled with pronounced elevation of mitochondrial mass and mtROS. Collectively, compound 2 emerges as a selective Ru-flavonol complex that drives pyroptosis-dominant cell death, a lytic, pro-inflammatory modality recognized to reprogram immunologically “cold” tumors into immune-vulnerable “hot” lesions.
SN  - 1422-0067
ER  -